Two other drugs are approved for moderate-to-severe Alzheimer's: memantine
(Namenda), which is the most commonly prescribed; and a combination of memantine
and donepezil (Namzaric), which together may have an additive effect.
Based on drug class, the global dementia associated with Alzheimer's disease market has been segmented into cholinergic/ cholinesterase (ChE) inhibitors, memantine
, and combined drug (memantine
& donepezil) and others.
'The promising data from our previous exploratory Phase 2 trial showed significant improvements in Severe Impairment Battery (SIB) scores for patients in the 20-microg Bryostatin-1 dose group not on memantine
, an NMDA antagonist.
Data from the previous exploratory Phase 2 trial demonstrated clear safety and showed greater than baseline improvements in Severe Impairment Battery scores that were sustained for patients in the 20microg Bryostatin-1 dose group not on memantine
. The current confirmatory Phase 2, multi-center trial is designed to assess the safety and efficacy of Bryostatin-1 as a treatment for cognitive deficits in 108 patients with moderate to severe AD who are not currently taking memantine
A pre-specified ANCOVA for baseline memantine
interaction with Bryostatin-1 and positive post-hoc trend analyses were statistically significant.
is a non-competitive NMDA receptor antagonist, with peculiar pharmacological properties, which explain its excellent safety and tolerability profile, at variance with the most potent NMDA receptor blockers such as ketamine, phencyclidine, and MK-801.
. Four 8- to 12-week RCTs in adults with OCD favored adjunctive memantine
, 20 mg/d, taken with an SSRI, over placebo.
The researchers looked at evidence from 142 clinical trials of four common cognitive enhancers--donepezil, rivastigmine (Exelon[R]), galantamine (Razedyne[R]) and memantine
He had trials of aripiprazole, then ziprasidone, and then guanfacine from November 2012 to May 2013 prior to starting memantine
to target his aggressive behaviors but they were reported to increase these behaviors and therefore discontinued.
The reason to revisit the first two forms of LTP in these mice was to investigate whether therapeutically relevant levels of the uncompetitive NMDA receptor antagonist, memantine
, could interfere with the properties of either of these NMDA receptor-dependent phenomena.
, an N-methyl-D-aspartate (NMDA) receptor antagonist, and donepezil, an acetylcholinesterase inhibitor (ACEI) are the most widely accepted agents in this regard.
is an antagonist of N-methyl-D-aspartate glutamate receptors as uncompetitively.